Fosaprepitant in Patients Receiving Ifosfamide-based Regimen
Status:
Completed
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn how different doses of fosaprepitant may
effect how ifosfamide-based chemotherapy is absorbed by the body. Researchers also want to
learn if fosaprepitant can help to control or prevent delayed nausea and/or vomiting that may
be caused by chemotherapy. The safety of this drug will also be studied.
Fosaprepitant is designed to block the natural substance in the brain that causes nausea and
vomiting. This may help to prevent and/or control nausea and vomiting caused by chemotherapy.